JP2023545494A5 - - Google Patents

Info

Publication number
JP2023545494A5
JP2023545494A5 JP2023522950A JP2023522950A JP2023545494A5 JP 2023545494 A5 JP2023545494 A5 JP 2023545494A5 JP 2023522950 A JP2023522950 A JP 2023522950A JP 2023522950 A JP2023522950 A JP 2023522950A JP 2023545494 A5 JP2023545494 A5 JP 2023545494A5
Authority
JP
Japan
Prior art keywords
capsule
release
controlled
composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023522950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545494A (ja
JP7874626B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/054991 external-priority patent/WO2022081848A1/en
Publication of JP2023545494A publication Critical patent/JP2023545494A/ja
Publication of JP2023545494A5 publication Critical patent/JP2023545494A5/ja
Application granted granted Critical
Publication of JP7874626B2 publication Critical patent/JP7874626B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023522950A 2020-10-16 2021-10-14 制御放出充填組成物およびそれを含むカプセル Active JP7874626B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063092679P 2020-10-16 2020-10-16
US63/092,679 2020-10-16
PCT/US2021/054991 WO2022081848A1 (en) 2020-10-16 2021-10-14 Controlled release fill compositions and capsules containing same

Publications (3)

Publication Number Publication Date
JP2023545494A JP2023545494A (ja) 2023-10-30
JP2023545494A5 true JP2023545494A5 (cg-RX-API-DMAC7.html) 2024-10-16
JP7874626B2 JP7874626B2 (ja) 2026-06-16

Family

ID=81209315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023522950A Active JP7874626B2 (ja) 2020-10-16 2021-10-14 制御放出充填組成物およびそれを含むカプセル

Country Status (13)

Country Link
US (1) US20230372252A1 (cg-RX-API-DMAC7.html)
EP (1) EP4228608A4 (cg-RX-API-DMAC7.html)
JP (1) JP7874626B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230088730A (cg-RX-API-DMAC7.html)
CN (1) CN116367864A (cg-RX-API-DMAC7.html)
AR (1) AR123800A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021360905B2 (cg-RX-API-DMAC7.html)
CA (1) CA3195386A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023005368A2 (cg-RX-API-DMAC7.html)
IL (1) IL301692A (cg-RX-API-DMAC7.html)
MX (1) MX2023004441A (cg-RX-API-DMAC7.html)
TW (1) TW202228655A (cg-RX-API-DMAC7.html)
WO (1) WO2022081848A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240099982A1 (en) * 2022-09-27 2024-03-28 Gaia Herbs Cellulose derivative free capsule for herbal extracts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5406530B2 (ja) * 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド 親水性ベヒクルに基づく二重制御された放出マトリクスシステム
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2850853A1 (en) * 2011-10-06 2013-04-11 Grunenthal Gmbh Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
WO2015200149A1 (en) * 2014-06-23 2015-12-30 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
CA2978269A1 (en) * 2015-03-02 2016-09-09 Bionpharma Healthcare Llc Immediate release soluble ibuprofen compositions
WO2016170097A1 (en) * 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
MX2017013634A (es) * 2015-04-24 2018-03-08 Gruenenthal Gmbh Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
US9943513B1 (en) * 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
WO2020068510A1 (en) * 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms

Similar Documents

Publication Publication Date Title
Ravi et al. Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization
JP6134788B2 (ja) 疎水性組成物のための生分解性薬物送達
JP6072121B2 (ja) リスペリドン徐放性ミクロスフェア組成物
AU2003240536B2 (en) Reduction of gelatin cross-linking
EP0977562B1 (en) Methods and compositions for delivery of taxanes
JPH10512845A (ja) テブフェロンの固体分散組成物
TWI838700B (zh) 口服紫杉烷組合物及方法
AU2007312233B2 (en) Micellar nanoparticles of chemical substances
JP2013216680A (ja) 親水性ベヒクルに基づく二重制御された放出マトリクスシステム
AU2015280262B2 (en) Fast acting orally disintegrating film
EP3881829A1 (en) Compositions comprising cyclosporin
DK2575784T3 (en) ORAL DOSAGE FORMS OF BENDAMUSTIN
JP2024163296A (ja) ソフトゲルにおけるａｐｉ安定性の向上
RU2557919C1 (ru) Сыпучий прессуемый порошок рапамицина и фармацевтическая композиция на его основе
WO2026081925A1 (zh) 酮康唑栓剂组合物及其制备和质量控制方法
CN114903904B (zh) 瑞马唑仑药用盐和阿片样物质的注射用药物组合物
US20140073670A1 (en) Pharmaceutical composition comprising fexofenadine
TW200824711A (en) Embedded micellar nanoparticles
CN108379227B (zh) 一种包载芦丁的聚合物胶束及其制备方法
CN105287402B (zh) 多西他赛聚合物胶束冻干制剂与专用溶剂的组合物
JP6605706B2 (ja) 保存安定性が向上した医薬組成物及びその製造方法
US11464736B2 (en) Thermally gelling drug formulations
Castro et al. Comparative plasma exposure of albendazole after administration of rapidly disintegrating tablets in dogs
JP4099537B2 (ja) ハードゼラチンカプセル及びハードゼラチンカプセルの製造方法
Sharma et al. Formulation and evaluation of mouth dissolving film of tadalafil